An adjustment for patient heterogeneity in the design of two-stage phase II trials

Statistics in Medicine

Volumn 28, Issue 20, 2009, Pages 2566-2579

  Sposto, Richard ^a,b   Gaynon, Paul S ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Cancer; Phase II; Stratification; Tumor response

Indexed keywords

ARTICLE; CONTENT VALIDITY; DATA ANALYSIS; HUMAN; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MATHEMATICAL VARIABLE; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PROBABILITY; PROBABILITY SAMPLE; SAMPLE SIZE; SIMULATION; STATISTICAL DISTRIBUTION; SYSTEMATIC ERROR; TREATMENT RESPONSE;

ALGORITHMS; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MODELS, STATISTICAL; NEOPLASMS; PATIENTS; RESEARCH DESIGN; SAMPLE SIZE; STATISTICAL DISTRIBUTIONS; TREATMENT OUTCOME;

EID: 70449348436     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3624     Document Type: Article

References (15)

1. Ensign LG, Gehan EA, Kamen DS, Thall PF. An optimal three-stage design for phase II clinical trials. Statistics in Medicine 1994; 13(17):1727-1736. (Pubitemid 24284855)
2. Brunier HC, Whitehead J. Sample sizes for phase II clinical trials derived from Bayesian decision theory. Statistics in Medicine 1994; 13:2493-2501.
3. Tan SB, Machin D. Bayesian two-stage designs for phase II clinical trials. Statistics in Medicine 2002; 21(14): 1991-2012. (Pubitemid 34752619)
4. Chen TT. Optimal three-stage designs for phase II cancer clinical trials. Statistics in Medicine 1997; 16(23): 2701-2711. (Pubitemid 27496916)
5. Chang MN, Therneau TM, Wieand HS, Cha SS. Designs for group sequential phase II clinical trials. Biometrics 1987; 43(4):865-874. (Pubitemid 18016772)
6. Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine 2003; 22(5):763-780.
7. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10(1):1-10. (Pubitemid 19099520)
8. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. British Journal of Haematology 2005; 131(5):579-587. (Pubitemid 43903802)
9. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel N, Twist C, Eckroth E, Sposto R, Gaynon P, Loh ML. Outcome of patients treated for relapsed or refractory Acute Lymphoblastic Leukemia (ALL) - a Therapeutic Advances in Childhood Leukemia (TACL) consortium study. Journal of Clinical Oncology 2009; in press.
10. Gorman MF, Ji L, Sposto R, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel N, Twist C, Eckroth E, Gaynon P, Loh M. Retrospective analysis of children treated for relapsed acute myelogenous leukemia: a report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium. Journal of Clinical Oncology 2008;
11. ASCO Meeting Proceedings (post-meeting edition), vol.26 (155) (May 20 supplement), Chicago, IL, 2008; 10042.
12. Webb DK, Wheatley K, Harrison G, Stevens RF, Hann IM. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia 1999; 13(1):25-31. (Pubitemid 29043713)
13. London WB, Chang MN. One and two-stage designs for stratified phase II clinical trials. Statistics in Medicine 2005; 24:2597-2611. (Pubitemid 41300797)
14. Anderson TW. An Introduction to Multivariate Statistical Analysis. Wiley: New York, 1958.
15. R Development Core Team. R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 2007.